Anzeige
Mehr »
Sonntag, 28.09.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken hat sich bewiesen - und American Critical sitzt direkt auf dem nächsten Milliardenfund
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMBV | ISIN: DK0061804770 | Ticker-Symbol: LDBA
Tradegate
26.09.25 | 19:23
5,945 Euro
-0,42 % -0,025
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
H LUNDBECK A/S B Chart 1 Jahr
5-Tage-Chart
H LUNDBECK A/S B 5-Tage-Chart
RealtimeGeldBriefZeit
5,9406,00019:03
5,9505,99026.09.

Aktuelle News zur H LUNDBECK Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoFDA turns down Lundbeck, Otsuka's Rexulti in PTSD on lack of efficacy data5
20.09.H. Lundbeck A/S: Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD718Valby, Denmark, 20 September 2025 - H. Lundbeck A/S (Lundbeck) and Otsuka America Pharmaceutical, Inc., (Otsuka) announce that Otsuka has received a Complete Response Letter (CRL) from the U.S. Food...
► Artikel lesen
11.09.H. Lundbeck A/S: Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti (eptinezumab) in patients severely impacted by migraine296Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress...
► Artikel lesen
10.09.Lundbeck wählt Swixx als wichtigsten Partner für eine transformative multiregionale Vereinbarung297Baar, Schweiz (ots/PRNewswire) - - Die Partnerschaft erstreckt sich über drei Regionen und positioniert Swixx als starken Akteur im Bereich der ZNS-Therapie - Baut auf dem globalen Pharmatrend des Outsourcings...
► Artikel lesen
10.09.HBM Healthcare Investments AG: HBM-Portfoliounternehmen Swixx BioPharma und Lundbeck unterzeichnen multiregionale Partnerschaft im Bereich ZNS385HBM Healthcare Investments AG / Schlagwort(e): Partnerschaft HBM-Portfoliounternehmen Swixx BioPharma und Lundbeck unterzeichnen multiregionale Partnerschaft im Bereich ZNS 10.09.2025...
► Artikel lesen
H LUNDBECK Aktie jetzt für 0€ handeln
10.09.Swixx Biopharma: Lundbeck Selects Swixx As A Key Partner In A Transformative Multi-Regional Deal428Partnership spans three regions, positioning Swixx as a strong player in CNS therapy area Builds on global pharma trend of outsourcing access and commercialization in the emerging marketsUnderscores...
► Artikel lesen
09.09.Lundbeck retreats from dozens of markets, slashing staff3
09.09.Lundbeck, in major resource reallocation, bows out of 27 markets and lays off 602 staffers2
09.09.H. LUNDBECK A/S: Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-20252
25.08.H. Lundbeck A/S: Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy279The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies...
► Artikel lesen
15.08.Lundbeck dials up migraine drug's US peak sales estimate, stays positive on Rexulti's PTSD use2
14.08.Lundbeck H1 2025 slides: Raises guidance as strategic brands drive 14% revenue growth3
13.08.H. Lundbeck A/S: Guidance raised based on solid H1 results and continued strong expectations for the full year 20251.800Key highlights Lundbeck's total revenue grew by +14% CER[1] (+14% DKK) to DKK 12,258 million in the first six months of 2025. Growth in the U.S. and Europe was the driver of this strong performance. United...
► Artikel lesen
13.08.H. LUNDBECK A/S: Lundbeck raises financial guidance for 202510
21.07.Lundbeck, Otsuka's PTSD bid for Rexulti dealt a setback at FDA advisory committee10
18.07.H. LUNDBECK A/S: Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting for the Treatment of Post-Traumatic Stress Disorder (PTSD)6
16.07.For Lundbeck and Otsuka's PTSD filing, FDA questions Rexulti efficacy after failed phase 34
24.06.Lundbeck's Lu AG13909 Secures Orphan Drug Status In US And EU For Rare Adrenal Disorder2
24.06.H. Lundbeck A/S: Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia292Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000-18,000 live births2A phase II trial has recently...
► Artikel lesen
21.06.H. Lundbeck A/S: New data demonstrates robust efficacy of Vyepti (eptinezumab) in otherwise difficult-to-treat patients with severe migraine626The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant...
► Artikel lesen
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1